Transfusion and Apheresis Science最新文献

{"title":"Comparing cryoprecipitate-poor plasma to fresh frozen plasma as replacement therapy in thrombotic thrombocytopenic purpura: An updated meta-analysis","authors":"Marcela Mafra ,&nbsp;Maria Meritxell Roca Mora ,&nbsp;Everton Castanha ,&nbsp;Amanda Godoi ,&nbsp;Andrés Valenzuela S","doi":"10.1016/j.transci.2024.104040","DOIUrl":"10.1016/j.transci.2024.104040","url":null,"abstract":"<div><h3>Background</h3><div>Cryoprecipitate-poor plasma (CPP) has been suggested as a promising alternative to the standard fresh frozen plasma (FFP) in plasma exchange therapy (TPE) for thrombotic thrombocytopenic purpura (TTP) given its lower concentrations of von Willebrand Factor (VWF). However, its efficacy and safety remain a topic of debate.</div></div><div><h3>Study design and methods</h3><div>We conducted a systematic review and meta-analysis comparing CPP to FFP during TPE in patients with TTP. PubMed, Embase, and Cochrane Central were systematically searched for studies reporting outcomes of all-cause mortality, relapse rate, response to treatment, and the mean number of TPE sessions. Sensitivity analyses restricted to randomized controlled trials (RCTs) were performed. Review Manager v5.4 and RStudio v4.1.2 were used for statistical analysis. The protocol was prospectively registered in PROSPERO (ID CRD42023440665).</div></div><div><h3>Results</h3><div>Eight studies, including three RCTs and five non-randomized studies, met the eligibility criteria. A total of 290 patients with TTP were included, of whom 144 (49.7 %) received CPP and 146 (50.3 %) received FFP. Use of CPP was associated with lower mortality (RR 0.41; 95 % CI 0.23–0.72; p = 0.002; I²=0 %), while the subgroup analysis restricted to RCTs showed no statistical difference between groups (p = 0.36). No significant differences were found in relapse rate, response to treatment, or mean number of TPE sessions between groups.</div></div><div><h3>Conclusion</h3><div>Our findings show that the use of CPP is not inferior to FFP in TPE. Given the limited population, future clinical trials are needed to elucidate its benefits compared to FFP in patients with TTP.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104040"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of febrile neutropenia episodes and blood product transfusions in children with acute leukemia","authors":"İrem Ceren Erbaş ,&nbsp;İlknur Akansu ,&nbsp;Özlem Tüfekçi Gürocak ,&nbsp;Şebnem Yılmaz ,&nbsp;Nurşen Belet ,&nbsp;Hale Ören","doi":"10.1016/j.transci.2024.104045","DOIUrl":"10.1016/j.transci.2024.104045","url":null,"abstract":"<div><h3>Objective</h3><div>Transfusion is vital supportive therapy in leukemias, but has significant potential febrile complications. In this study, we aimed to reveal the possible effects of blood product transfusions on febrile neutropenia episodes (FNEs) in children with acute leukemia.</div></div><div><h3>Methods</h3><div>We obtained the relevant clinical and laboratory data from the medical records.Transfusions of red blood cell (RBC), platelet (PLT), and fresh frozen plasma (FFP) administered during FNE were recorded in detail.</div></div><div><h3>Results</h3><div>A total of 80 children with acute leukemia were included. A total of 235 FNE were investigated and the median age at first FNE was 4.72 years. At least one blood product transfusion was administered in 80.9 % (n = 190) of the patients with FN. The need for RBC, PLT, and total transfusions was higher in patients with AML and who were &gt; 4 years-old. Bacteremia, gram-negative bacteria, and polymicrobial infections were more frequent in patients who received PLT transfusions. Complications were increased in patients who had ≥ 3 transfusions and had received multiple FFP and pooled PLT transfusions. Patients who received pooled PLT during previous FNE had an increased risk of death.</div></div><div><h3>Conclusions</h3><div>Complications were more frequent, neutrophil count was lower, durations of neutropenia and medical treatment were longer in patients who had ≥ 3 transfusions.Bacteremia, gram-negative bacteria, and polymicrobial infections were more common in children who received PLT transfusions. Therefore, patients who need multiple transfusions, especially PLT and FFP transfusions, should be closely followed up during their FNE in terms consequences of transfusion as well as severity of underlying infection.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104045"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five year follow -up of a university initiated national voluntary non remunerated blood donation programme in a developing country","authors":"Kenneth S. Charles ,&nbsp;Rykel. Rojas ,&nbsp;Melina De Four ,&nbsp;Melissa Friday","doi":"10.1016/j.transci.2024.104042","DOIUrl":"10.1016/j.transci.2024.104042","url":null,"abstract":"<div><div>International bodies continue to recommend blood services based on voluntary non remunerated blood donation as an essential prerequisite for blood safety and adequacy. Trinidad and Tobago is a multi-ethnic, multi-religious, high income developing country with a long history of family replacement and remunerated blood donation. Delivery of blood services is fragmented across <strong>five</strong> autonomous Regional Health Authorities and policy is established by the National Blood Transfusion Service in the Ministry of Health. A voluntary non remunerated blood donor programme initiated by The University of the West Indies at one blood donation centre collected 1.8 % of the annual donations in its first three years and was accepted for national extension in 2018. The COVID-19 pandemic delayed implementation of this plan. The programme to achieve exclusive voluntary non remunerated donation nationally was launched by the Ministry of Health on World Blood Donor Day, June 14th 2022. Knowledge, attitude and practices surveys were done to gather information for communication and interventional strategies. Voluntary non remunerated blood donation was linked to restructuring of blood transfusion services across all Regional Health Authorities. Fifteen surveys identified misconceptions, knowledge gaps and socially acceptable methods of intervention. Voluntary non remunerated donations accounted for 10.8 % of the national collection in the first full year of implementation (<em>p</em> &lt; 0.05). A voluntary non remunerated blood donation programme based on research, education and action has been successfully extended nationally.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104042"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biographies of the guest editors for the theme papers on graft-versus-host disease (GVHD)","authors":"Serdal Korkmaz,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104050","DOIUrl":"10.1016/j.transci.2024.104050","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104050"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful of autologous hematopoietic stem cell mobilization with plerixafor combined with G-CSF in pediatric neuroblastoma patients, a single center experience","authors":"Leila Jafari ,&nbsp;Fatemeh Hematyar ,&nbsp;Yalda Karamlou ,&nbsp;Nadia Alipour ,&nbsp;Rashin Mohseni ,&nbsp;Fahimeh Jafari ,&nbsp;Zeynab Nikfetrat ,&nbsp;Maryam Behfar ,&nbsp;Amir Ali Hamidieh","doi":"10.1016/j.transci.2025.104067","DOIUrl":"10.1016/j.transci.2025.104067","url":null,"abstract":"<div><h3>Background</h3><div>Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric. In highrisk NB patients, the 5-year overall survival rate (OS) remains a stark &lt; 50 % with conventional therapies. Autologous hematopoietic stem cell transplantation with high dose chemotherapies was used in poor prognosis and high-risk patients.Today, Plerixafor is used to increase stem cells mobilization in patients who are candidates for autologous transplantation.</div></div><div><h3>Objective</h3><div>This study examined safety and efficacy Plerixafor is administered as a subcutaneous injection in pediatric NB patients for stem cell mobilization</div></div><div><h3>Study Design</h3><div>A cohort of 19 pediatric neuroblastoma (NB) patients underwent autologous hematopoietic stem cell transplantation (HSCT) between February 2017 and April 2019, receiving G-CSF mobilization only. Subsequently, 37 NB patients underwent HSCT between December 2019 and October 2023, receiving both G-CSF and plerixafor for mobilization (auto-HSCT).</div></div><div><h3>Results</h3><div>The final product CD34 cell dose /kg was evidently higher in combination group at 5.363 ± 4.243 vs. G-CSF group at 2.827 ± 3.586 × 106(P value= 0.001). Neutrophils and platelet engraftment were occurred sooner in combination group compared with G-CSF group. The 1-year overall survival (OS) rate for the G-CSF and G-CSF-and-plerixafor combination group was 70.8 % and 63.3 %, respectively (P = 0.874). No statistically significant difference in OS or disease-free survival (DFS) was observed between the two treatment groups.</div></div><div><h3>Conclusion</h3><div>The results show that plerixafor may be safe and effective in NB pediatric patients in routine clinical practice. It was well tolerated in NB patients and no specific side effects were observed. It was not associated with improved survival.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104067"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How rare is rare? The first multi-centre epidemiological study of thrombotic thrombocytopenic purpura in a large Canadian city","authors":"Brandon Tse,&nbsp;Megan Buchholz,&nbsp;Christopher Patriquin,&nbsp;Katerina Pavenski","doi":"10.1016/j.transci.2024.104065","DOIUrl":"10.1016/j.transci.2024.104065","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104065"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What’s Happening- Editorial Commentary: Reflections on \"Platelet-Omics\", focusing on Diagnostic, Development, Research [DDR] Strategies on the use of Omics to better understand platelet physiology and platelet-based therapies","authors":"Jerard Seghatchian","doi":"10.1016/j.transci.2024.104059","DOIUrl":"10.1016/j.transci.2024.104059","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104059"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood use and alloimmunization in myelodysplastic syndrome patients: A study of a hospital transfusion experience","authors":"Wenhao Xu ,&nbsp;Chunkang Chang","doi":"10.1016/j.transci.2024.104041","DOIUrl":"10.1016/j.transci.2024.104041","url":null,"abstract":"<div><h3>Background</h3><div>Patients with myelodysplastic syndrome (MDS) are characterized by chronic anemia and most of them require transfusion making them prone to developing transfusion dependence (TD) and inducing red blood cell (RBC) alloimmunization. Little information is available regarding the status of transfusions of MDS patients in China.</div></div><div><h3>Materials and methods</h3><div>Clinical history and transfusion information of MDS transfusion patients from 2004 to 2023 were collected from electronic medical and laboratory records. TD patients were divided into increased blasts (IB) and non-IB group. Blood component transfusion was evaluated and compared in different groups using Mann-Whitney and chi-square tests.</div></div><div><h3>Results</h3><div>A total of 893 MDS patients received a median of 13 (range, 0 - 436) RBC units and 10 (range, 0 - 216) platelets (PLT) units. Seventy-one (8 %) patients formed 106 RBC specific antibodies of which Rh system was the most (82/106 = 77 %). Twelve patients (17 %) had 14 antibodies (13 %) evanescence whereas 7 patients had former antibodies reemerge. Alloimmunization was more common in female, older patients and patients with larger RBC transfusions. Among 222 TD patients, RBC transfusion and alloimmunization rate in IB group were lower than those in non-IB group whilst PLT was the opposite.</div></div><div><h3>Conclusions</h3><div>Prophylactic Rh system compatible transfusion can reduce the risk of RBC alloimmunization in MDS patients’ especially in TD and non-IB patients and can prevent reinduction of antibody evanescence. To our knowledge this is the first study we reveal RBC antibody induction and evanescence which may related to different disease stages and classifications of MDS patients</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104041"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of discrepancy between clot-based and chromogenic factor IX coagulation assays in non-severe hemophilia B patients and identification of the causing mutations","authors":"Mahdieh Mahdavimand ,&nbsp;Shadi Tabibian ,&nbsp;Alireza Zafarani ,&nbsp;Rima Manafi ,&nbsp;Mahmood Barati ,&nbsp;Majid Safa","doi":"10.1016/j.transci.2024.104063","DOIUrl":"10.1016/j.transci.2024.104063","url":null,"abstract":"<div><h3>Background</h3><div>Hemophilia B, or Christmas disease, is a hemorrhagic inherited disorder. Previous studies have reported measurement discrepancies in factor VIII activity between clot-based and chromogenic assays in approximately one-third of patients with non-severe hemophilia A. However, similar discrepancies in hemophilia B have been less extensively studied. This research compares clot-based and chromogenic assays in 33 patients with non-severe hemophilia B and investigates the mutations associated with these discrepancies.</div></div><div><h3>Methods</h3><div>Citrate and EDTA samples were collected from 33 patients with non-severe hemophilia B at Iran's hemophilia comprehensive care center. Clinical information was also gathered. Both clot-based and chromogenic assays were performed on these patients. DNA was extracted from the EDTA samples for those with discrepancies in the test results, and PCR was conducted to sequence their genes to find mutations.</div></div><div><h3>Results</h3><div>Among 33 plasma samples from patients with non-severe hemophilia B, 7 showed a measurement discrepancy according to the definition of ISTH (&lt;0.5, &gt;2.0, or an absolute difference &gt;10), which includes both reverse and classic types of discrepancies. In this study, mutations that previously did not show contradictory results now exhibit discrepancies. A difference in classification was observed in 21 % of the patients.</div></div><div><h3>Conclusions</h3><div>The findings indicate that the impact of specific mutations varies depending on the assay conditions. In addition to mutations, other factors also play a role in this discrepancy. Both types of assays are essential for the accurate diagnosis and classification of hemophilia B.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104063"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Ruxolitinib in the management of chronic GVHD","authors":"Asli Odabasi Giden ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Ipek Yonal Hindilerden ,&nbsp;Emine Hidayet ,&nbsp;Ilhami Berber ,&nbsp;Tarik Onur Tiryaki ,&nbsp;Tugba Zorlu ,&nbsp;Sinem Namdaroglu ,&nbsp;Ahmet Sarici ,&nbsp;Elif Aksoy ,&nbsp;Esra Yildizhan ,&nbsp;Muruvvet Seda Aydin ,&nbsp;Serdal Korkmaz ,&nbsp;Mehmet Sinan Dal ,&nbsp;Turgay Ulas ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104053","DOIUrl":"10.1016/j.transci.2024.104053","url":null,"abstract":"<div><h3>Objectives</h3><div>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for hematological diseases, with success rates improving due to advancements in conditioning regimens and new anti-graft versus host disease (GVHD) drugs. Ruxolitinib, an oral selective Janus kinase (JAK) 1 and 2 inhibitor has been used to mitigate the effects of various inflammatory and myeloproliferative syndromes, given the JAK kinase pathway's central role in cytokine signaling during inflammatory and immune processes. In this study we aimed to assess ruxolitinib's efficacy in patients with chronic GVHD (cGVHD).</div></div><div><h3>Material and methods</h3><div>This retrospective observational multi-center study involved 50 patients diagnosed with cGVHD after allo-HSCT in Turkey, who were treated with ruxolitinib between April 2018 and March 2024.</div></div><div><h3>Results</h3><div>At the time of initiation of ruxolitinib treatment, most patients had severe cGVHD (n = 29, 58 %). The overall response rate at 6 months of ruxolitinib treatment was observed in 34 patients (68 %), including 6 patients (12 %) with complete responses and 28 patients (56 %) with partial responses, while 7 patients (14 %) experienced treatment failure. ECOG (2−4) performance status was established as an independent risk factor for adverse outcomes [p = 0.029, HR 3.492 (95 % CI: 1.139–10.705)]. At the two-year follow-up, the estimated survival rate was 52 %.</div></div><div><h3>Conclusion</h3><div>Ruxolitinib is safe and effective in the real-world setting for treating cGVHD, showing remission rates comparable to clinical trials. Further research with extended follow-up is necessary to confirm these findings, optimize dosing, and establish the best tapering strategies for responders.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104053"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}